Loading
Finerenone Placebo / Acute Heart Failure / Finerenone Oral Tablet · Phase 4 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
FACILITATE-HF is a Phase 4 randomized controlled trial currently recruiting participants to evaluate whether early finerenone initiation in hospitalized acute heart failure patients improves a composite outcome of death or worsening heart failure within 12 weeks. No results are reported in this registry record, and the trial remains open to enrollment.
Phase 4, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Acute Heart Failure; age from 18 Years. Intervention: Finerenone. Compared with: Placebo — Placebo Comparator. n = 550. 21 sites: Japan.
FACILITATE-HF is a Phase 4 randomized controlled trial currently recruiting participants to evaluate whether early finerenone initiation in hospitalized acute heart failure patients improves a composite outcome of death or worsening heart failure within 12 weeks. No results are reported in this registry record, and the trial remains open to enrollment.
This is a registry record with no results posted; no efficacy or safety data are available for interpretation.
The source did not state who this applies to in practice.
This is a registered but actively recruiting Phase 4 trial with no reported results; the study design is sound but outcomes are not yet available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07397650). This is a study registration, not published results. Lead sponsor: Juntendo University. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 550 participants (ESTIMATED). Conditions: Acute Heart Failure. Interventions: DRUG: Finerenone Oral Tablet; DRUG: Finerenone Placebo. Primary outcome measures: A hierarchical composite endpoint of death and worsening heart failure , Up to 12 weeks. Brief summary: FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.